H.C. Wainwright Keeps Their Buy Rating on TherapeuticsMD (TXMD)

By Austin Angelo

In a report issued on March 27, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on TherapeuticsMD (TXMDResearch Report), with a price target of $6.00. The company’s shares closed last Monday at $1.08, close to its 52-week low of $0.90.

According to TipRanks.com, Tsao is a 2-star analyst with an average return of -0.5% and a 46.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Minerva Neurosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for TherapeuticsMD with a $10.67 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.04 and a one-year low of $0.90. Currently, TherapeuticsMD has an average volume of 4.06M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. is a pharmaceutical company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.